Ibn-1, a new diabetes drug in Changshan pharmaceutical industry, is expected to be approved in the near future
-
Last Update: 2015-03-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the website information of CFDA on March 16, the clinical application status of ibonatide injection and API, a new class 1 drug of Changshan Pharmaceutical Co., Ltd., is "under approval", which means that the drug has completed the technical approval and entered the final stage of submission to CFDA for signature Ibn is an intestinal hypoglycemic analog developed by Changshan kaijiejian, a joint venture of Changshan pharmaceutical and CO njuchem LLC in 2012, for the treatment of type 2 diabetes Previously, the product has completed phase I and phase II clinical trials in the United States and Canada According to the research data, ibuprofen has the advantages of long half-life, good clinical tolerance, once a week administration, and definite effect Ibn is an important strategy for Changshan pharmaceutical industry to diversify its products If it can be successfully developed, it will reduce the risk of the company's excessive dependence on heparin products Changshan Pharmaceutical Co., Ltd is mainly engaged in heparin series products There are only two kinds of heparin preparations: low molecular weight heparin calcium injection and heparin sodium injection The company's performance is easily affected by the price fluctuation of API and preparation products.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
